Navigating the Cybersecurity Landscape for MedTech

Why this matters

The FDA's Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions (Feb 3, 2026 final guidance) made cybersecurity documentation a gating criterion for clearance under Section 524B of the FD&C Act. Reviewers apply this guidance to MedTech submissions the same way they apply software lifecycle expectations from IEC 62304 and security risk-management expectations from AAMI TIR57 and ANSI/AAMI SW96:2023.

Gaps in this area are the single most common driver of first-cycle cybersecurity Additional Information (AI) requests. The FDA's FY2024 CDRH performance reports show cybersecurity is among the top deficiency categories cited in 510(k) and PMA AI letters, behind only software documentation and clinical evidence. Treating it as a checklist exercise rather than a design-controlled engineering artifact is what creates the gap.

Establishing a Strong Quality Management System with ISO 13485

In medical technology, cybersecurity is now a defining concern for MedTech teams. As Christian Espinosa, the CEO and founder of Blue Goat Cyber, explains, one foundational element in keeping medical devices safe and secure is a quality management system built to the ISO 13485 standard.

ISO 13485 is the international standard that sets out the requirements for a quality management system in the medical device industry. It is designed to ensure that medical devices are consistently designed, manufactured, and delivered to meet the needs of patients and healthcare providers. Central to ISO 13485 is traceability, which lets manufacturers maintain a record of the design, production, and performance of their devices.

As Christian explains, “The whole idea is when you have a medical device, you need to have a QMS or some system that has basically all the information about the medical device. The design history files, cybersecurity documentation, and the overall concept are that I have all this information organized in a very logical manner. I have traceability for when the device was in the market, as well as for when it was designed, built, and tested. I have that full visibility and traceability in the system.”

This traceability matters when addressing any issue that arises with a medical device. With a well-documented QMS, manufacturers can quickly identify the root cause of a problem, implement corrective actions, and demonstrate to regulatory bodies that they have taken the steps needed to mitigate risks and protect patients.

Cybersecurity: The Leading Cause of FDA Rejections

One of the most significant challenges facing MedTech innovators today is the increasing scrutiny placed on the cybersecurity of their devices. As Trevor Slattery, the Chief Technology Officer and Director of MedTech Cybersecurity at Blue Goat Cyber, explains, “Lately, in the past year or so, the most common reason is cybersecurity. Actually, insufficient or inadequate cybersecurity, I should say.”

This trend is particularly concerning, as the FDA’s primary focus is on ensuring patient safety. When a medical device is vulnerable to cyber threats, it poses a direct risk to the well-being of the individuals who rely on it. As a result, the FDA has placed a greater emphasis on evaluating the cybersecurity measures implemented by MedTech companies during the device approval process.

To address this issue, MedTech innovators must adopt a proactive approach to cybersecurity, integrating it into the design and development of their devices from the outset. This includes conducting thorough risk assessments, implementing security controls, and ensuring that their quality management system contains documentation of their cybersecurity measures.

HIPAA vs FDA Cybersecurity: What's the Difference?

A common area of confusion for MedTech teams is the distinction between the Health Insurance Portability and Accountability Act (HIPAA) and the FDA's expectations on cybersecurity.

As Christian explains, "The FDA is primarily concerned with patient safety. Meaning, if I can hack into this medical device, what harm can I cause to a patient? That is a primary lens the FDA is looking for. HIPAA, in contrast, is related to protected health information. It has nothing to do with patient safety. Is my charting about my diagnosis protected? Is my insurance protected for my hospital treatment? These are two very different things."

The distinction matters for MedTech teams, because HIPAA compliance alone does not satisfy the FDA's cybersecurity requirements. Protecting patient data matters, but the FDA's primary focus is on whether the device itself is secure enough to prevent patient harm.

To address both sets of obligations, MedTech teams need a cybersecurity strategy that maps to both HIPAA and FDA expectations. That can mean adding security controls, running deeper risk assessments, and making sure the QMS documents the cybersecurity work in full.

SAMD vs. SIMD: Regulatory Differences

Another area of complexity for MedTech teams is the distinction between Software as a Medical Device (SAMD) and Software in a Medical Device (SIMD). As Christian explains, "SAMD is software as a medical device. This would be some software that may reside in the cloud. It could be an AI image enhancement tool that takes an ultrasound image, sends it to the cloud, and the software component runs AI on it, performing image enhancement for conditions such as vascular disease. Therefore, the physician can examine the image and view the vascular portion more clearly than just through ultrasound or an MRI. A SIMD is software in a medical device, and it is essentially a medical device that incorporates software. This could be, for example, a patient monitoring system that has software built into it."

Understanding the differences between SAMD and SIMD matters, because each often requires a different regulatory approach and different cybersecurity controls. SAMD, being a standalone software product, may be subject to other security requirements than SIMD, which is integrated into a physical medical device.

MedTech teams need to evaluate their products and follow the regulatory guidelines that fit their specific software-based medical technology. That can mean engaging with regulatory bodies, such as the FDA, to make sure their cybersecurity controls line up with the relevant standards.

Global Regulatory Demands: How They Differ

Cybersecurity regulation for medical devices is uneven across regions, with different countries imposing their own requirements. As Christian and Trevor explain, the FDA and China are often considered the strictest.

See also: When to Hire a Device Security Consultant vs. Build In-House, Cybersecurity Is Now a QMS Requirement, and Why Medical Device Cybersecurity Is Nothing Like Enterprise.

According to Christian, "Typically, I would say it's the FDA, which basically borrows from the IMDRF, but has elaborated on that quite a bit. And then I know China has some stringent requirements as well. So I would I would say between those two, but I I think the FDA is more global reaching than China, which is more specific to China."

The regulatory differences between the FDA and China are a real challenge for MedTech teams. As Trevor points out, "Ironically, if you're FDA cleared, you can sell your device to the Hong Kong market, which is a special administrative region of China, and then once it's been adopted in the Hong Kong market, then it can be sold to the China market and bypass Chinese approval, which is especially a good strategy to take considering oftentimes Chinese clearance for the NMPA requires a complete device overhaul as opposed to some minor documentation modifications, which may be the case, say, going from the US to South Korea."

To meet these obligations across markets, MedTech teams have to track the cybersecurity requirements in each target jurisdiction, engage with regulatory bodies, and build a strategy that satisfies the standards in every market they plan to sell into.

Conclusion: Actionable Insights for MedTech Teams

Cybersecurity for medical devices keeps changing, and MedTech teams have to stay alert to keep their products safe. By acting on the concepts and regulatory points above, teams can take proactive steps that protect both their devices and the patients who use them.

As Christian Espinosa puts it, "We want to do the best we can to make sure MedTech innovators are armed with the cybersecurity knowledge and that the knowledge we're providing is actually actionable and there can be some specific actions taken upon it to prevent their device from getting rejected or delayed to market."

Stay alert, stay current on the regulations, and stay secure.

Key Takeaways:

• ISO 13485 is the international standard for a quality management system in the medical device industry, with traceability, quality, and documentation at its core.
• Cybersecurity is now the most common reason for FDA rejection of medical devices, as the agency's primary focus is on patient safety.
• HIPAA and FDA regulations have different focuses, with HIPAA primarily concerned with protecting patient data and the FDA focused on preventing harm to patients.
• Understanding the differences between Software as a Medical Device (SAMD) and Software in a Medical Device (SIMD) matters for getting your regulatory strategy right.
• The FDA and China set the strictest cybersecurity expectations for medical devices, with the FDA having a more global reach.
• MedTech teams need to track the latest regulatory requirements, engage with regulators, and build cybersecurity strategies that keep their devices secure and compliant.

Table of Contents

• Establishing a Quality Management System with ISO 13485
• Cybersecurity: The Leading Cause of FDA Rejections
• HIPAA vs FDA Cybersecurity: What's the Difference?
• SAMD vs. SIMD: Regulatory Differences
• Global Regulatory Demands: How They Differ
• Key Takeaways:

How Blue Goat approaches this

Blue Goat Cyber's medical device practice is led by engineers with CISSP, OSCP, and prior military red-team backgrounds. We treat cybersecurity documentation as design-controlled engineering output, not a submission template, every artifact (threat model, SBOM, security risk assessment, penetration test, labeling) traces back to a controlled requirement and a verified result.

Our engagements deliver the full Feb 3, 2026 guidance documentation set scoped to the device's risk profile, integrated with the existing IEC 62304 software lifecycle and ISO 14971 risk file. See our medical device cybersecurity services for the full scope. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost.

FAQ

Why is cybersecurity a leading cause of FDA medical device rejections?

The FDA's primary concern is patient safety. Insufficient cybersecurity in a medical device can pose direct risks to patient well-being, leading the agency to reject devices that lack adequate security measures.

What is the difference between FDA cybersecurity regulations and HIPAA?

The FDA focuses on preventing patient harm from device vulnerabilities, while HIPAA primarily protects the privacy and security of protected health information (PHI). Compliance with HIPAA does not guarantee compliance with FDA cybersecurity requirements.

What is SAMD vs. SIMD?

SAMD (Software as a Medical Device) is standalone software that functions as a medical device, often cloud-based. SIMD (Software in a Medical Device) is software integrated into a physical medical device. Each has distinct regulatory and cybersecurity considerations.

When did the FDA release its final premarket cybersecurity guidance?

The FDA released its final premarket cybersecurity guidance on February 3, 2026. This guidance outlines the agency's expectations for cybersecurity in medical device submissions.

How does ISO 13485 relate to medical device cybersecurity?

ISO 13485 establishes requirements for a quality management system in the medical device industry. It ensures traceability and documentation, which are foundational for integrating and managing cybersecurity throughout a device's lifecycle.

Does FDA clearance simplify global market access for medical devices?

FDA clearance can facilitate market access in some regions, such as Hong Kong and subsequently mainland China, often bypassing more extensive local approvals. However, MedTech innovators must still understand and meet specific cybersecurity regulations for each target market.